RA0324

antibody from Oursmab

Targeting: IGHE

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0324

Provider

Oursmab

Product name

Ligelizumab (Biosimilar Reference Antibody) (IGHE)

Antibody type

Monoclonal

Description

Ligelizumab (also known as QGE031) is an investigational, humanized monoclonal antibody that targets immunoglobulin E (IgE) with higher affinity than the clinically established antibody omalizumab. It binds to the C¦Å3 domain of IgE, the same region that interacts with the high-affinity IgE receptor (Fc¦ÅRI) on mast cells and basophils. By doing so, ligelizumab prevents IgE from binding to Fc¦ÅRI, thereby inhibiting the allergen-induced cross-linking and activation of these cells that leads to the release of histamine and other inflammatory mediators. It is being developed for the treatment of moderate-to-severe allergic asthma, chronic spontaneous urticaria (CSU), and other IgE-mediated allergic conditions.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg-500,10 mg,25 mg,50 mg,484 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.